Cerecor (NASDAQ:CERC)‘s stock had its “buy” rating reaffirmed by investment analysts at Maxim Group in a research report issued to clients and investors on Tuesday, AnalystRatings.com reports. They currently have a $10.00 target price on the stock. Maxim Group’s price objective would suggest a potential upside of 188.18% from the company’s previous close.

Other equities analysts have also recently issued reports about the stock. HC Wainwright set a $11.00 price target on shares of Cerecor and gave the stock a “buy” rating in a research report on Wednesday, August 21st. ValuEngine raised shares of Cerecor from a “hold” rating to a “buy” rating in a research report on Thursday, August 1st. Finally, LADENBURG THALM/SH SH reissued a “buy” rating and set a $8.00 price target on shares of Cerecor in a research report on Tuesday, July 2nd. Four investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus price target of $9.67.

Shares of NASDAQ CERC traded up $0.05 during midday trading on Tuesday, reaching $3.47. 27,912 shares of the stock were exchanged, compared to its average volume of 55,199. The business has a 50-day simple moving average of $3.25 and a two-hundred day simple moving average of $4.49. Cerecor has a 12 month low of $2.71 and a 12 month high of $7.65. The company has a current ratio of 0.74, a quick ratio of 0.71 and a debt-to-equity ratio of 0.81.

Cerecor (NASDAQ:CERC) last announced its quarterly earnings results on Thursday, August 8th. The company reported ($0.13) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.16) by $0.03. The company had revenue of $4.45 million for the quarter, compared to analysts’ expectations of $5.28 million. Cerecor had a negative net margin of 231.68% and a negative return on equity of 143.30%. Equities research analysts predict that Cerecor will post -0.57 EPS for the current year.

In related news, Director Armistice Capital, Llc acquired 9,886 shares of the company’s stock in a transaction that occurred on Friday, August 16th. The shares were acquired at an average cost of $3.43 per share, for a total transaction of $33,908.98. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, major shareholder Armistice Capital Master Fund acquired 2,200,000 shares of the company’s stock in a transaction that occurred on Friday, September 6th. The shares were bought at an average price of $3.05 per share, for a total transaction of $6,710,000.00. The disclosure for this purchase can be found here. Over the last 90 days, insiders have purchased 4,643,678 shares of company stock worth $14,224,147. 64.30% of the stock is currently owned by company insiders.

Hedge funds have recently modified their holdings of the business. Vanguard Group Inc. lifted its stake in shares of Cerecor by 56.5% during the second quarter. Vanguard Group Inc. now owns 678,000 shares of the company’s stock worth $3,689,000 after purchasing an additional 244,657 shares in the last quarter. BlackRock Inc. boosted its position in shares of Cerecor by 4,046.6% during the second quarter. BlackRock Inc. now owns 1,205,533 shares of the company’s stock worth $6,559,000 after buying an additional 1,176,460 shares during the period. Northern Trust Corp boosted its position in shares of Cerecor by 47.4% during the second quarter. Northern Trust Corp now owns 55,971 shares of the company’s stock worth $304,000 after buying an additional 17,999 shares during the period. Bank of New York Mellon Corp boosted its position in shares of Cerecor by 294.9% during the second quarter. Bank of New York Mellon Corp now owns 57,428 shares of the company’s stock worth $312,000 after buying an additional 42,885 shares during the period. Finally, Charles Schwab Investment Management Inc. acquired a new position in shares of Cerecor during the second quarter worth approximately $288,000. Hedge funds and other institutional investors own 55.75% of the company’s stock.

Cerecor Company Profile

Cerecor Inc, a pharmaceutical company, focuses on pediatric health care. Its lead product portfolio includes prescribed dietary supplements, such as Poly-Vi-Flor and Tri-Vi-Flor; and prescription drugs, such as Millipre, Ulesfia, Karbinal ER, AcipHex Sprinkle, and Cefaclor for oral suspension, as well as Flexichamber a medical device.

Further Reading: What is the Fibonacci sequence?

Receive News & Ratings for Cerecor Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cerecor and related companies with MarketBeat.com's FREE daily email newsletter.